FTRE Share Price Performance
US$17.85
13.40 (301.12%)
10.1% overvalued intrinsic discount
US$16.21
Fair Value
Price US$17.85
AnalystConsensusTarget US$16.21
AnalystHighTarget US$20.00
AnalystLowTarget US$9.50
Fair ValueUS$16.21
Share Pricen/a
Fortrea Holdings Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 9 Fair Values set on narratives written by author
FTRE Community Narratives
AN
Fair Value
·Fair Value US$16.21 10.1% overvalued intrinsic discount
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
Fair Value
·Fair Value US$20 10.8% undervalued intrinsic discount
Global Aging And Digital Trends Will Reshape Clinical Research
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value
·Fair Value US$9.5 87.9% overvalued intrinsic discount
Regulation And Pricing Will Erode Margins But May Improve Efficiency
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
FTRE: Stabilizing Healthcare Trends Will Support Resilience Amid Mixed Market Signals
Fortrea helps drug and medical device makers run clinical trials, and steady healthcare demand could lift the business as the market steadies. But heavy reliance on a handful of big customers and tough competition may limit how quickly results improve.Read more
AN
US$16.21
10.1% overvalued intrinsic discount
Fair Value
Profit Margin
15.57%
Future PE
5.11x
Price in 2029
US$21.13
Regulation And Pricing Will Erode Margins But May Improve Efficiency
Fortrea faces a tough squeeze as regulators, drug pricing pushback, and bigger clients gain more bargaining power—putting pressure on growth and profitability. But if it can cut costs, modernize its tech, and keep strong ties with major drugmakers, the same industry trends could set it up for a stronger comeback than the market expects.Read more
AN
US$9.5
87.9% overvalued intrinsic discount
Fair Value
Profit Margin
15.57%
Future PE
3.05x
Price in 2029
US$12.3
Global Aging And Digital Trends Will Reshape Clinical Research
Fortrea is trying to turn clinical research into a leaner, more digital business, using automation and new software to cut waste and win higher‑value work as drug trials grow more complex. But a heavy reliance on a handful of big customers and intense price competition could derail the turnaround if new projects don’t come in as expected.Read more
AN
US$20
10.8% undervalued intrinsic discount
Fair Value
Profit Margin
1.7%
Future PE
56.74x
Price in 2029
US$26.03
Trending Discussion
Recently Updated Narratives
AN
FTRE: Execution On 2026 Guidance And AI Rollout Will Shape Risk Reward
Fair Value: US$16.21 10.1% overvalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FTRE: Ongoing Execution Risks Around 2026 Guidance Will Limit Upside Potential
Fair Value: US$9.5 87.9% overvalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
FTRE: Conservative 2026 Guidance And AI Tools May Drive Re Rating
Fair Value: US$20 10.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Fortrea Holdings Inc. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -4.72
- 18.86%
- -16.50%
- 200.4%
About FTRE
- Founded
- 2023
- Employees
- 14000
- CEO
- WebsiteView website
Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services. The company also provides consulting services comprising product development and regulatory, market access and health economics, and outcomes research, as well as RWE services. Fortrea Holdings Inc. was incorporated in 2023 and is headquartered in Durham, North Carolina.
